Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 9007-72-1
Drug Levels and Effects
Summary of Use during Lactation
Intravenous iron carboxymaltose increases breastmilk iron in mothers with iron deficiency anemia. Breastfed neonates of these mothers appear to have no serious adverse reactions. Ferric carboxymaltose appears to be acceptable to use in nursing mothers with no special precautions required. For additional information on iron use during breastfeeding, see the monograph on Iron Salts.
Drug Levels
Maternal Levels. A multi-center study of postpartum mothers with iron deficiency anemia (hemoglobin 105 g/L or less) compared iron carboxymaltose to oral ferrous sulfate. Mothers were given intravenous ferric carboxymaltose in a dose of 15 mg of iron/kg body weight to a maximum dose of 1000 mg over 15 minutes on day 1, with subsequent weekly doses until each woman's total iron requirement had been given. The first dose was given within 7 days postpartum and follow-up visits were at follow-up visits after 1, 2, 4, and 12 weeks postpartum. A subset of 11 mothers had their breastmilk iron measured before and after administration of iron carboxymaltose. Baseline breastmilk iron was 0.500 mg/kg. At 24 hours after the first dose, breastmilk iron increased to 1.447 mg/kg. One week after the first dose, breastmilk iron decreased to an average of 0.513 mg/kg. After the second dose at week 1, breastmilk iron increased to 0.615 mg/kg at 1 to 3 hours after the dose. Breastmilk iron was 0.991 mg/kg before the dose on week 2.[1]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
In a study of postpartum mothers given intravenous ferric carboxymaltose, 229 were breastfeeding their infants. Among the breastfed infants, 24 infants (10.5%) had an adverse reaction reported. The most frequent reactions included erythema, constipation, diarrhea and nasopharyngitis. The overall rate of adverse reactions was similar to the rate (12%) in the control group whose mothers received oral ferrous sulfate.[1]
In a study of mothers with postpartum anemia, 16 women were given 1000 mg ferric carboxymaltose intravenously as a single dose, either alone (n = 8) or in combination with a red blood cell transfusion (n = 8). At the time of the iron infusion, 13 of the women were exclusively or fully breastfeeding and 2 were partially breastfed. No adverse effects in breastfed infants were reported.[2]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
- Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008;101:67-73. [PubMed: 18234203]
- 2.
- Caljé E, Oyston C, Wang Z, et al. The fatigue after infusion or transfusion pilot trial and feasibility study: A three-armed randomized pilot trial of intravenous iron and blood transfusion for the treatment of postpartum anemia. Transfusion 2023. [PubMed: 38149691]
Substance Identification
Substance Name
Ferric Carboxymaltose
CAS Registry Number
9007-72-1
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Review Iron Sucrose.[Drugs and Lactation Database (...]Review Iron Sucrose.. Drugs and Lactation Database (LactMed®). 2006
- Review Ferric carboxymaltose: a review of its use in iron deficiency.[Drugs. 2015]Review Ferric carboxymaltose: a review of its use in iron deficiency.Keating GM. Drugs. 2015 Jan; 75(1):101-27.
- Review Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.[Drugs. 2009]Review Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.Lyseng-Williamson KA, Keating GM. Drugs. 2009; 69(6):739-56.
- Review Ferric Carboxymaltose: A Review in Iron Deficiency.[Drugs. 2018]Review Ferric Carboxymaltose: A Review in Iron Deficiency.Scott LJ. Drugs. 2018 Mar; 78(4):479-493.
- Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer(®) ) versus ferric carboxy-maltose (Ferinject(®) ). A single center, cohort study.[Br J Clin Pharmacol. 2019]Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer(®) ) versus ferric carboxy-maltose (Ferinject(®) ). A single center, cohort study.Mulder MB, van den Hoek HL, Birnie E, van Tilburg AJP, Westerman EM. Br J Clin Pharmacol. 2019 Feb; 85(2):385-392. Epub 2018 Dec 11.
- Ferric Carboxymaltose - Drugs and Lactation Database (LactMed®)Ferric Carboxymaltose - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...